Engineering of a Long-Acting Relaxin for the Treatment of Pulmonary Hypertension
- Using a biophysics-based approach to engineer a long-acting relaxin molecule for chronic therapy
- Showing that TX45 is effective in a rat model of severe pulmonary hypertension
- In parallel we used the well-established effects of relaxin on renal plasma flow in both rats in healthy volunteers to demonstrate the high degree of in vitro to in vivo correlation and the translatability of these effects for our optimized molecule